Table 1.
Demographic characteristics, comorbidities, clinical presentation, and clinical outcomes.*.
| Population[n = 177] | |
|---|---|
| Demographics | |
| Age, median (IQR), years | 68 (52–80) |
| Age≥ 65 years old,% (N) | 55.9 (99/177) |
| Males,% (N) | 57.6 (102/177) |
| Nosocomial,% (N) | 1.7 (3/177) |
| Long-term care resident,% (N) | 4 (7/177) |
| Health professional,% (N) | 4 (7/177) |
| WavesFirst (1.02.2020 - 31.05.2020),% (N)Second (1.06.2020 - 15.12.2020),% (N)Third (16.12.2020 - 31.03.2021),% (N) | 54.2 (96/177)31.1 (55/177)14.7 (26/177) |
| Antibiotic therapy in the previous 3 months | 28.8 (51/177) |
| Comorbidities | |
| Hypertension,% (N) | 55.9 (99/177) |
| Diabetes,% (N) | 26.6 (47/177) |
| Current or former Smoker,% (N) | 20.6 (70/177) |
| Obesity,% (N) | 39.7 (56/141) |
| Chronic respiratory disease,% (N) | 21.6 (38/177) |
| Immunosuppression,% (N) | 4 (7/177) |
| Charlson comorbidity index, median (IQR) | 3 (1–6) |
| Charlson index ≥3,% (N) | 59.3% (105/177) |
| 10-years expected survivala | 53.3 (1.6–90.1) |
| Clinical Presentation | |
| Median time (IQR) from symptom to hospitalization, daysb | 6 (3–7) |
| Fever,% (N) | 67.2 (119/177) |
| Cough,% (N) | 26.0 (46/177) |
| Dyspnoea,% (N) | 57.6 (102/177) |
| Diarrhoea,% (N) | 25 (447,177) |
| Confusion,% (N) | 9.6 (17/177) |
| Fatigue,% (N) | 41.0 (71/173) |
| Myalgias-arthralgias,% (N) | 30.1 (52/173) |
| Anosmia-dysgeusia,% (N) | 6.9 (12/173) |
| Initial Assessment | |
| Oximetry <94% at room air,% (N) | 43.7% (73/167) |
| PaO2:FiO2, median (IQR) | 332 (272–404) |
| Respiratory rate, breaths/min, median (IQR) | 18 (16–24) |
| Systolic BP, mmHg, median (IQR) | 130 (118–145) |
| Diastolic BP, mmHg,median (IQR) | 78 (68–89) |
| Temperature, °C,median (IQR) | 36.9 (36.3–37.7) |
| Heart rate, beats/min, median (IQR) | 92 (81–102) |
| eGFR, ml/min/m2, median (IQR) | 73 (47–90) |
| Lymphocytes, per mm3, median (IQR) | 910 (700–1370) |
| Lymphopenia,% (N) | 44.3 (78/176) |
| C-reactive protein > 10 mg/dL,% (N) | 33.1 (55/175) |
| Procalcitonin > 0.5 ng/mL,% (N) | 12.4 (20/161) |
| Ferritin > 500 mg/L,% (N) | 59.8 (98/164) |
| Lactate dehydrogenase > 250 U/L,% (N) | 33.9 (53/156) |
| D-dimers > 1 mg/mL,% (N) | 33.1 (53/160) |
| Interleukin 6 ≥ 10 pg/mL,% (N) | 77.7 (101/130) |
| Troponin T > 14 ng/L,% (N) | 49.4 (77/176) |
| Brain natriuretic peptide > 125 pg/mL,% (N) | 53.5 (84/157) |
| Potassium mmol/L, median (IQR) | 4.1 (3.8–4.4) |
| Pneumonia on X-rays,% (N) | 89.2 (157/176) |
| Opacities >50% of lung surface on X-rays,% (N) | 21.5 (38/177) |
| Treatment | |
| Corticosteroids,% (N) | 46.3% (82/177) |
| Remdesivir,% (N) | 3.9% (7/177) |
| Tocilizumab,% (N) | 23.7% (42/177) |
| Outcomes | |
| Non-invasive mechanical ventilation requirement,% (N) | 23.1 (41/177) |
| Invasive mechanical ventilation requirement,% (N) | 11.3 (20/177) |
| Mortality,% (N) | 17.5 (31/177) |
⁎
Data shown as%, median (interquartile range, IQR), unless specified otherwise. In bold, statistically significant differences. Percentages may not total 100 because of rounding.
a
10-years expected survival derived from Charlson comorbidity index score.
b
Days of symptoms before admission. OR: odds ratio, 95%CI: 95% confidence interval.